Multiple publications carrying out sequencing or immunohistochemistry to study mRNA/protein levels of DYRK2 have suggested that DYRK2 is a tumor suppressor in colorectal (60, 61, 62, 63), liver (64), brain (65), and lung cancers (66, 67) and that the kinase promotes chemosensitivity in ovarian cancer (68). Here, DYRK2 is linked to neoplasm.